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Abstract
Background: Ataxia is a sign of different disorders involving any level of the nervous system and consisting of
impaired coordination of movement and balance. It is mainly caused by dysfunction of the complex circuitry
connecting the basal ganglia, cerebellum and cerebral cortex.
A careful history, physical examination and some characteristic maneuvers are useful for the diagnosis of ataxia.
Some of the causes of ataxia point toward a benign course, but some cases of ataxia can be severe and particularly
frightening.
Methods: Here, we describe the primary clinical ways of detecting ataxia, a sign not easily recognizable in children.
We also report on the main disorders that cause ataxia in children.
Results: The causal events are distinguished and reported according to the course of the disorder: acute,
intermittent, chronic-non-progressive and chronic-progressive.
Conclusions: Molecular research in the field of ataxia in children is rapidly expanding; on the contrary no similar
results have been attained in the field of the treatment since most of the congenital forms remain fully untreatable.
Rapid recognition and clinical evaluation of ataxia in children remains of great relevance for therapeutic results and
prognostic counseling.
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Background
Ataxia in children is a common clinical sign of various
origins consisting of impaired coordination of movement
and balance with a lack of muscle control during volun-
tary activity [1, 2]. Ataxia is most frequently caused by
dysfunction of the complex circuitry connecting the
basal ganglia, cerebellum and cerebral cortex, and this
type of involvement is recorded as “cerebellar ataxia.”
The term “sensory ataxia” [3, 4] refers to the dysfunction
of the proprioceptive sensory activity correlated with the
peripheral nerves or to the posterior columns of the
spinal cord.
Clinical signs in cerebellar ataxic patients are related to
impaired localization. Focal dysfunction of the cerebellar
vermis displays truncal unbalance, nystagmus and head
waddling, and the impairment of the cerebellar hemi-
spheres results in an anomalous gait veering toward the
affected side, with asymmetry of the ipsilateral extremities
and a high-stepping gait. Involvement of afferent/sensory
ataxia manifests as a stepping gait and sensory damage of
the extremities.
How to recognize ataxia in children: common signs and
maneuvers
Cerebellar ataxia may manifest with several signs and
symptoms, the most common being a staggering gait,
asynergic movements, dysmetria, nystagmus, intentional
tremor and difficulty in forming speech. A through
history and a careful clinical examination are important
ways to recognize anomalous movements and to
* Correspondence: ppavone@unict.it
1University-Hospital “Policlinico-Vittorio Emanuele”, University of Catania,
Catania, Italy
6Unit of Pediatrics and Pediatric Emergency, Azienda Ospedaliera
Universitaria Vittorio Emanuele-Policlinico, University of Catania, Italy, Via
Plebiscito 767, 95123 Catania, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pavone et al. Italian Journal of Pediatrics  (2017) 43:6 
DOI 10.1186/s13052-016-0325-9
distinguish involvement of the cerebellum from other
affected areas of the nervous system.
Typical signs and specific maneuvers may be of great
help in revealing childhood ataxia. This can be evaluated
in various conditions: in a sitting position, in which the
affected child manifests a loss of truncal control, and
during walking, in which the patient exhibits a tandem
gait or a veering toward the affected side. The recogni-
tion of ataxia is particularly difficult in early childhood.
The most common cerebellar symptom is unsteadiness
of gait. The child stands with feet widely separated and
rapidly lose his balance. On attempting to walk, the
child sways and stops, and may walk backward. In some
cases, incoordination of the eye movements may be
present. After the age of 3 years, the semiology of ataxia
is similar to that of adulthood. The coordination may be
explored through typical maneuvers such as finger to
finger or finger to nose, and rapid alternating hand
movements (Fig. 1). Heal to knee dysregulation (Fig. 2)
and dysmetria observed through errors in fixing the
correct distance (too long or too short) may be of diagnos-
tic value. Slurred speech, scarring and poor expression are
signs of cerebellar involvement. Sensory tactile, painful,
thermal, and profound evaluation must be registered; any
abnormalities should accordingly be carefully checked.
Two simple but useful maneuvers for revealing ataxia in
children are the Romberg sign, expressed by the tendency
to fall down with closed eyes in a holding position, and
the test of holding a full glass of water with a steady
hand without any of the water spilling (Fig. 3) [5, 6].
Many conditions may show ataxia as one of their
primary clinical signs. In some case, ataxia may be
expressed as a rapid and benign course, and it is some-
times manifested as a progressive and severe neuro-
logical involvement.
According to its etiology, ataxia may be displayed as a
condition that is acquired, inherited or sporadic. The
course of ataxia may be distinguished as being acute,
intermittent and recurrent, chronic-non-progressive and
chronic-progressive.
Fig. 1 Finger to nose maneuver
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Temporal course distinction must be taken in a
broad sense and with the awareness that the same dis-
order may have a different course, depending on the
age of presentation, time of the diagnosis (precocious
or late). This is particularly true for brain tumors that
usually have a progressive course, but in very young
children may present with a quite acute onset. At the
same time, brainstem and cerebellar malformations are
correctly included in the group of chronic non-
progressive ataxias, but if the disorder is identified pre-
cociously, it could be included in the group of chronic
progressive ones.
Ataxia in children as one of the main clinical signs of
different disorders is reported in the following sections
and discussed on the basis of its temporal course.
1. Acute ataxia
The most common causes of acute ataxia in
children are excessive drug ingestion, drug
intoxications and post-infectious cerebellitis.
Antiepileptic drugs that may cause ataxia include
benzodiazepines (diazepam, clobazam, nitrazepam),
oxcarbamazepine, lamotrigine and phenytoin [7–9]
and antineoplastic/immunosuppressive agents such
as cyclosporine, tacrolimus, cytosine arabinoside
and similar drugs [1]. Ataxia may also be related
to intoxications to various elements such as alcohol,
ethylene glycol, lead, mercury, thallium, lithium and
toluene [10, 11].
Low intake of the vitamins thiamine, cobalamin,
vitamin E, zinc and folate in neglected children or
Fig. 2 Heal to knee maneuver
Fig. 3 Specific maneuver consisting in holding a full glass of water
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in children affected by intestinal disorders may
results in symptoms of ataxia [1–3].
Varicella is one of the primary infectious agents
that affects the cerebellum. The disorder may hit
children of all ages, but it is most prevalent
between the ages of 2 and 8 years. In this case,
ataxia begins 2–6 days after the onset of rash, but
it may also occur during the incubation period or
after resolution of the rash [12]. Among the other
involved infectious agents, cerebellar impairment
may manifest itself after mumps or infectious
mononucleosis. Syphilis and Whiplle’s disease,
HIV, and Kawasaki disease may also be causes
of ataxia [1–3]. Labyrinthitis is often associated
to ataxia and is difficult to differentiate from
acute cerebellar ataxia.
The recent discoveries on immunomediated
disorders have increased the number of the
various affections that exhibit signs of ataxia.
One of the most controversial is the association
of ataxia with antigliadin antibodies, so-called
“gluten ataxia.” Children presumed to be affected
by this disorder present gait ataxia, nystagmus,
peripheral neuropathy and brain involvement
upon MRI as a consequence of a gluten trigger.
A gluten-free diet has been reported to improve
the clinical signs in the affected patients [13].
In a systematic review and metanalysis led by
Lionetti et al. [14], the presence of cerebellar
gluten-ataxia was documented in two large
studies and reported in 2.7 and 5.4% of patients,
respectively; no correlation was found between
coeliac patients and ataxia in two other study-
analyses. Patients with malignancies—mainly
patients with Hodgkin’s lymphoma and other
types of neoplasms—may present ataxia. Anti-
Purkinje cells, anti-Yo (type 1), anti Hu, and anti
Ri antibodies have been reported in affected
patients [15]. Antibodies to glutamic acid
decarboxylase associated with thyroid disorders
and/or insulin-dependent diabetes mellitus may
manifest ataxia as one of the presenting signs [16],
but this disorder is rare among children. In the
group of thyroid disorders, the autoimmune
thyroiditis also called Hashimoto encephalopathy
may manifest with ataxia. This severe condition
presents a progressive course and behavioral
changes such as aggressivity and psychotic crises,
sensory dulling, headache, memory deficits, tremor,
myoclonus, and, in the most severe cases, coma
[17, 18]. Ataxia is one of the components of
ophthalmoplegia and areflexia of the triad of
Miller-Fisher syndrome, which belongs to the
group of Guillain-Barrè syndrome and is linked to
the presence of the antibody anti CQ1B. Diagnosis of
this syndrome is obtained via an analysis of cerebral
liquor, which displays a dissociation between high
CSF protein levels and a low or absent leucocyte
response [19].
2. Intermittent and remittent ataxia
Basilar migraine, “episodic ataxias” (EAs) including
benign paroxysmal ataxia may manifest with ataxia.
Basilar migraine is part of the subgroup of
headaches, and intermittent ataxia is one of the
signs of this condition, together with impaired
vision, dysarthria, dizziness and occasional loss of
consciousness. Familiarity, recurrence of headache
episodes, and normality of the neurologic
examination are elements that often lead to a
diagnosis of basilar migraine [20]. EAs represent a
clinically heterogeneous groups of conditions with
recurrent bouts of abrupt-onset of ataxia lasting
minutes to hours. Clinical manifestations may
also include vomiting, vertigo, headache, dysarthria,
diplopia and dystonic attacks. Eight subtypes have
been recently distinguished according to clinical and
genetic characteristics and 5 genes are recognized to
be linked to EAs more common being KCNA1 and
CACNA1A genes mutations [21]. Some of these
disorders, mainly the types 2, 3, and 5 EAs have
shown a good response to treatment with
acetazolamide [22].
Some inborn errors of metabolism may present
with intermittent ataxia. An example of this
condition is Hartnup disease, an autosomal
recessive (AR)-inherited disorder due to an
abnormal renal and gastrointestinal transport
of neutral amino acids. The primary sign of
this disorder is cutaneous photosensitivity. Sun
exposure in affected children causes cutaneous
redness, and a pellagra-like rash that is severely
pruritic. Some patients show an intermittent,
unsteady, wide-based gait. Prognosis is usually
benign [23–25]. Maple syrup urine disease
(MSUD) is an AR disorder that involves
branched-chain amino acids. The diagnosis is
based on the classical sweet smell of maple syrup
of the urines. Several phenotypes of MSUD are
recognized: in the intermittent MSUD type
during stress or an infectious episode, children
may present vomiting and ataxia. When not
treated, the disorder can lead to lethargy until
coma [26, 27]. Pyruvate dehydrogenase complex
deficiency is typically a severe disorder with different
clinical aspects and biochemical presentations. In
older children, the enzyme activity may be partially
present and result in mild-to-moderate hyperlactic
acidemia and ketoacidosis following stress, infectious
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episodes and high carbohydrate ingestion. This
disorder is clinically associated with frequent
episodes of ataxia, vomiting and breathing
difficulties [28, 29].
Mutations in genes coding for ion channels and
transport proteins are associated with hereditary
episodic ataxia and vertigo [30, 31].
3. Chronic-non-progressive ataxias
This group includes the outcome of patients
suffering from stroke and hypoxic-ischemic
encephalopathy outcome. This condition is the
most frequent cause of cerebral damage with
an incidence rate of 1.5 individuals per 1000
newborns. The cerebral involvement is linked
in about 90% of cases to perinatal asphyxia that
acts through two linked pathogenetic mechanisms:
hypoxia with reduced hematic O2 concentration
and ischemia with lowered cerebral perfusion [32].
The affected children show several manifestations
with cognitive delay, epileptic seizures, spasticity,
impairment of voluntary movements and
coordination and neuro-behavioral anomalies
such as aggressivity and restlessness [3].
Chronic ataxic manifestations that are typically
not progressive may be found within two cerebral
malformation syndromes: Dandy-Walker syndrome
(DWS) and Arnold-Chiari malformation (ACM).
The first syndrome is characterized by an
enlargement of the fourth ventricle, the complete
absence of cerebellar vermis and cystic formation
near the internal base of the skull. In ACM, the
affected children show a downwards displacement
of the cerebellar tonsils through the foramen
magnum with a presumed risk to complicate with a
non-obstructive hydrocephalus.
Multiple sclerosis in young children may initially
manifest as intermittent ataxia [1, 3, 6].
Ataxia is one of the signs indicative of cerebellar
malformation in which the cerebellum can be
totally or partially involved. The most well-known
form is Joubert’s syndrome, an AR disorder due to
a congenital ponto-cerebellar hypoplasia (PCH).
Affected patients present neonatal hypotonia, ocular
motor apraxia, breathing difficulties and multiple
systemic involvement. More than 20 causative genes
of Joubert’s syndrome have been recognized, most of
which are related to proteins of the primary cilium, a
subcellular organelle that carries out specific cellular
functions. Diagnosis may be based on a typical
sign of the molar tooth observed in the brain
MRI of affected patients. The sign is related to the
extension of the cerebellar superior peduncles in
association with the depth interpeduncular furrow
that resembles the shape of a molar tooth [33, 34].
Lack of development and/or early
neurodegeneration of cerebellum and brainstem are
the main characteristics of PCH. These conditions
encompasses a constellation of genetic conditions
with involvement of several genes and distinctive
clinic-radiological phenotypes [35].
The pathologic anomalies of PCH consist of
distinctive features including a reduced number
of cellular folia and poor folial branching,
degeneration and disappearance of pontine nuclei,
fragmentation of dentate nuclei, variable
degenerative changes and poor branching of the
inferior olivar nuclei [36].
4. Cerebellar progressive ataxias.
Inherited ataxias include a heterogenous group
of clinically and genetically distinguished
neurodegenerative disorders. The most well-known
of the inherited ataxias include autosomal dominant
cerebellar ataxia reported as spino-cerebellar ataxias
(SCAs) and autosomal recessive cerebellar ataxias
(ARCAs). X-linked inherited forms and ataxia
associated with mithochondrial disorders are also
included in this group (Figs. 4 and 5).
Presently, more than 35 types of SCAs are
recognized. The forms of SCAs are categorized
according to the number assigned to the gene loci
from SCA1 to SCA37. Dentato-rubral-
pallidoluysian atrophy (DRPLA) belongs to this
group. Some of these forms are caused by the
expansion of microsatellite repeats (SCA 1–3, 6–8,
10, 12, 17, 31, 36). Expansion of polyglutamine
coding CAG repeats are related to the forms SCAs
Fig. 4 Sagittal T1-weighted MRI images of a 3-year-old aged patient
presenting ponto-cerebellar dysplasia
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1–3, 6, 7 and 17, and the expansion of non-coding
repeats are related to SCAs 8, 10, 12, 31 and 36.
Point mutations are linked to the other forms.
Ataxia, with a variable age of onset, from congenital
to adult, and a variable course ranging from non-
progressive to slowly progressive, is related to a
single type of SCA. Associations with ophthalmologic
and auditory anomalies, hypotonia, cognitive delay
and sensory anomalies may be a component of
each of these forms [1, 37–41]. SCA type 3
(Machado-Joseph disease) is a well-known
disorder. Affected patients exhibit both ataxia
and pyramidal signs and peripheral amyotrophy,
nystagmus, ophthalmoparesis and bulging eyes.
Fasciculations involve the face, tongue and limbs.
Dystonia and movement disorders are also
associated [4, 42].
X-linked SCAs include the Fragile X syndrome
associated with tremor/ataxia syndrome with
mutations in the FMR1 gene. Mutations in
mitochondrial DNA may manifest themselves
with ataxia, myopathy, external ophthalmoplegia,
endocrine deficiencies, short stature and retinal
pigmentary degeneration [43, 44].
ARCAs are distinctive disorders linked to cerebellar
and spinal cord degeneration. The most well-known
ARCAs include Friedreich’s ataxia (FA) and ataxia
teleangectasia. Both of these disorders are inherited
with autosomal recessive inheritance. FA involves
the chromosome 9 GAA trinucleotide expansion.
This disorder strongly affects the afferent/sensory
circuits and the cerebellum. Its primary symptoms
consist of ataxia, pes cavus, scoliosis and areflexia.
Hypertrophic cardiomyopathy is a relevant sign
present in affected children [45, 46]. Ataxia
teleangectasia involves chromosome 11. Over
200 mutations involving the ATM gene have
been reported. The primary symptoms consist
of progressive truncal ataxia, oculo-cutaneous
teleangectasias, polyneuropathy, hypotonia and
oculomotor apraxia. Teleangectasia is more
frequently localized on the conjunctivae but is
also found in ear lobes and the popliteal fossa (Fig. 6).
Low levels of circulating immunoglobulins (IgA, IgM,
IgG and IgE), together with lymphocytopenia and
increased alpha-fetoprotein, are reported. Recurring
infections of the upper and lower respiratory tracts
have been quoted [47, 48]. Ataxia with oculomotor
apraxia (AOAs) is a group of recessive disorders
associated to FA. Children with AOAs manifest
ataxia, oculomotor apraxia, polyneuropathy and,
in some cases, also dysarthria, choreoatetosis and
dystonia. Cognitive delay may be present. In patients
with AOA type 2 axonal neuropathy, cerebellar
atrophy and increased levels of alpha-fetoprotein are
found. Movement disorders are also present [49, 50].
Ataxias are signs reported in other AR disorders
such as SeSAME syndrome (seizures, sensoneural
deafness, ataxia, mental retardation and electrolyte
unbalance) and in SYNC1 ataxia (spinocerebellar
ataxia, spinocerebellar atrophy, and cerebellar ataxia
and coenzyme Q10 deficiency (ARCA2) [51, 52].
Recently, cerebellar ataxia has been linked to
mutations in the PEX10 gene related to
peroxisomal biogenesis disorders in a young
patient with marked cerebellar atrophy [53].
Autosomal recessive spastic ataxia of Charlevoix
Seguenay is a complex disorder characterized by
spasticity, ataxia, polyneuropathy and amyotrophy
of distal muscles. Chromosome 13 is involved with
over 70 mutations that have been reported in the
SAC genes [54–56]. Marinesco-Sjogren syndrome
exhibit cerebellar ataxia, myopathy with
progressive muscular hypotonia, cognitive
delay and congenital cataracts, often associated
with skeletal deformities, short stature and
hypogonadotropic hypogonadism [57, 58].
Congenital errors of metabolism may show ataxia
among the other progressive severe neurologic
involvement. Examples of these disorders include
some types of gangliosidoses, lipidoses and
adrenoleukodystrophy. Abetalipoproteinemia
(Bassen-Kornzeig disease) is an AR disorder linked
to a mutation in microsomal triglyceride transfer
protein (MTTP) genes. Steatorrhea and a failure
to thrive are the initial signs later followed by
Fig. 5 Coronal T1-weighted MRI image of an 8-year-old patient
affected by cerebellar dysplasia. The cerebellum is markedly
hypotrophic, and the lateral ventricles are wide
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ataxia, retinitis pigmentosa, peripheral neuritis,
muscle weakness and cognitive delay. A blood smear
is diagnostic with acanthocytosis together with low
blood levels of cholesterol and triglycerides and the
absence of beta-lipoproteins. The disorder is associated
with malabsorption of lipids and lipid-soluble vitamins
(i.e. A, D, E, and K) [59].
Cerebral tumors, particularly medulloblastoma,
cerebellar astrocytoma, brain stem glioma and
ependymomas, are among the most common
causes of progressive ataxia in children [31].
The clinical onset of cerebral tumors is frequently
preceded by episodes of headaches and vomiting
followed rapidly by additional signs or symptoms.
Warming signs beyond morning vomiting and
headaches include specific neurologic symptoms
such as seizures, vision difficulties and frontal
and occipital pain. There is a progression of
the symptoms both in frequency and intensity
with exacerbation given a change of position
or movement. Mood changes with irritability,
aggressivity and nocturnal awakening are also
relevant diagnostic signs. Ataxia associated
with myoclonus and opsoclonus is a
characteristic sign of medulloblastoma [60, 61].
In all the types of cerebral tumors, brain
imaging represents the best way to obtain a
correct diagnosis.
Fig. 6 Typical teleangectasias localized on the conjunctivae of a 7 year-old patient
Fig. 7 Clinical flow-chart of Ataxia
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Treatment
Some advances have been obtained in some of the
disorders with ataxia. Treatment of EAs with acet-
azolamide and GLT1SD with ketogenic diet gave good
results [21, 22]. However, a really few hereditary dis-
eases associated with ataxia may be fully treatable.
Symptomatic treatment and supportive management
may alleviate the course of these severe disorders.
Conclusions
Recognizing ataxia in children may be challenging. It may
be overlooked mainly in very young children and errone-
ously related to a delay of coordination. Physical examin-
ation and correct maneuvers are useful for highlighting its
clinical sign. The causal events of ataxia are several and
have different outcomes that may range from transient
and benign to particularly severe and frightening. Pediatri-
cians must be skilled at differentiating treatable disorders
from progressive, degenerative and devastating ones, some
of which are singularly difficult to diagnose. For most of
these disorders, there is no curative care available; only
supportive treatment is suitable. A flowchart of the
primary causes of ataxia is listed in Fig. 7.
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